This brand name is authorized in Austria, France, Lithuania, Romania, United States
The drug FRUZAQLA contains one active pharmaceutical ingredient (API):
1
Fruquintinib
UNII 49DXG3M5ZW - FRUQUINTINIB
|
Fruquintinib is a selective tyrosine kinase inhibitor of VEGFR-1, -2, and -3 with antitumor effects resulting from suppression of tumour angiogenesis. |
Below package inserts are available for further reading:
Title | Information Source | Document Type | |
---|---|---|---|
FRUZAQLA Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC | |
FRUZAQLA Hard capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
L01EK04 | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: FR | Base de données publique des médicaments | Identifier(s): 63200612, 64771069 |
Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1100271, 1100272 |
Country: RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | Identifier(s): W70451001, W70452001 |
Country: US | FDA, National Drug Code | Identifier(s): 63020-210, 63020-225 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.